The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients – An analysis of NRG Oncology/Gynecologic Oncology Group trials
- 1 December 2016
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (3) , 490-495
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (CA 27469, CA 37517, 1 U10CA180822)
This publication has 39 references indexed in Scilit:
- Prognostic factors for high‐risk early‐stage epithelial ovarian cancerCancer, 2008
- Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survivalBritish Journal of Cancer, 2008
- Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?Gynecologic Oncology, 2007
- Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancerGynecologic Oncology, 2006
- The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinomaEuropean Journal of Surgical Oncology, 2006
- Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian StudyJournal of Clinical Oncology, 2005
- Prolonged Disease-Free Survival after One Course of Perioperative Adjuvant Chemotherapy for Node-Negative Breast CancerNew England Journal of Medicine, 1989
- Combination Adjuvant Chemotherapy for Node-Positive Breast CancerNew England Journal of Medicine, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Use of Ranks in One-Criterion Variance AnalysisJournal of the American Statistical Association, 1952